NovaBay Pharma Announces Special Cash Dividend

NovaBay Pharma ( (NBY) ) just unveiled an announcement.

On August 26, 2025, NovaBay Pharmaceuticals announced a special cash dividend of $0.80 per share, payable on September 29, 2025, to stockholders of record as of September 15, 2025. This decision follows an investment agreement with David E. Lazar, who has committed up to $6 million in exchange for preferred stock. The dividend aims to maximize shareholder value after the sale of NovaBay’s eye care products to PRN Physician Recommended Nutriceuticals, LLC earlier in the year. The NYSE American has advised that the company’s stock will trade with ‘due bills’ during the dividend right period, affecting stockholders who sell their shares during this time.

The most recent analyst rating on (NBY) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on NovaBay Pharma stock, see the NBY Stock Forecast page.

Spark’s Take on NBY Stock

According to Spark, TipRanks’ AI Analyst, NBY is a Neutral.

NovaBay Pharma’s overall stock score reflects significant financial challenges, with declining revenues and negative profit margins being the most impactful factors. Despite positive technical indicators suggesting bullish momentum, the stock is overbought, which could lead to a correction. The strategic shift with a new CEO and investment agreement provides a positive outlook, but the negative valuation metrics weigh heavily on the score.

To see Spark’s full report on NBY stock, click here.

More about NovaBay Pharma

NovaBay Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of products for the eye care market under the Avenova brand.

Average Trading Volume: 3,111,518

Technical Sentiment Signal: Sell

Current Market Cap: $5.28M

For a thorough assessment of NBY stock, go to TipRanks’ Stock Analysis page.